May 15, 2006 – AstraZeneca will pay $1.1 billion to acquire the 80% of Cambridge Antibody Technology it does not already own; Advancis received FDA approval for two new strengths of its antibiotic, Keflex; Artes Medical, a dermotology company, filed for its IPO; OXiGENE won Orphan Product designation for its ovarian cancer drug; GTX began a Phase II trial of ostarine for osteoporosis; Advaxis reported positive results for its Listeria cervical cancer vaccines in pre-clinical testing; Hemispherx Biopharma began testing flu vaccine and its Ampligen immunopotentiation adjuvant in a Phase II trial; and Marshall Edwards inlicensed two cancer drugs from its majority owner, Novogen Limited of Australia. The Centient Biotech 200™ closed with a 13 point gain at 3717.95, an increase of .36%. More details...
